XTX Topco Ltd Sells 27,943 Shares of Pediatrix Medical Group, Inc. $MD

XTX Topco Ltd reduced its holdings in Pediatrix Medical Group, Inc. (NYSE:MD) by 62.4% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,809 shares of the company’s stock after selling 27,943 shares during the quarter. XTX Topco Ltd’s holdings in Pediatrix Medical Group were worth $241,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. American Century Companies Inc. grew its position in shares of Pediatrix Medical Group by 28.6% during the 2nd quarter. American Century Companies Inc. now owns 1,931,867 shares of the company’s stock worth $27,722,000 after buying an additional 430,029 shares during the period. Rhumbline Advisers lifted its position in shares of Pediatrix Medical Group by 1.3% during the 2nd quarter. Rhumbline Advisers now owns 219,833 shares of the company’s stock valued at $3,155,000 after acquiring an additional 2,887 shares during the period. Franklin Resources Inc. boosted its stake in Pediatrix Medical Group by 8.5% during the second quarter. Franklin Resources Inc. now owns 64,469 shares of the company’s stock worth $925,000 after acquiring an additional 5,050 shares in the last quarter. Legal & General Group Plc grew its holdings in Pediatrix Medical Group by 1.0% in the second quarter. Legal & General Group Plc now owns 235,882 shares of the company’s stock worth $3,385,000 after purchasing an additional 2,294 shares during the period. Finally, Brandywine Global Investment Management LLC bought a new stake in Pediatrix Medical Group in the second quarter valued at $5,310,000. 97.71% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Pediatrix Medical Group

In other news, Director Michael A. Rucker sold 10,478 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $23.00, for a total value of $240,994.00. Following the completion of the sale, the director owned 59,101 shares in the company, valued at $1,359,323. This represents a 15.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Laura A. Linynsky sold 10,000 shares of the firm’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $21.65, for a total transaction of $216,500.00. Following the transaction, the director directly owned 32,232 shares in the company, valued at $697,822.80. The trade was a 23.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.90% of the stock is currently owned by company insiders.

Pediatrix Medical Group Stock Performance

Shares of MD opened at $21.21 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 1.83. The stock has a 50 day moving average price of $20.13 and a two-hundred day moving average price of $16.59. The firm has a market capitalization of $1.82 billion, a P/E ratio of 11.16 and a beta of 0.77. Pediatrix Medical Group, Inc. has a 52 week low of $11.84 and a 52 week high of $24.99.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Monday, November 3rd. The company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.21. The company had revenue of $492.88 million for the quarter, compared to analyst estimates of $476.45 million. Pediatrix Medical Group had a return on equity of 20.45% and a net margin of 8.44%.The company’s revenue for the quarter was down 3.6% on a year-over-year basis. During the same quarter last year, the company earned $0.44 earnings per share. Equities analysts forecast that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on MD shares. Truist Financial upped their price objective on shares of Pediatrix Medical Group from $17.00 to $24.00 and gave the company a “hold” rating in a report on Monday, November 10th. Leerink Partners boosted their target price on Pediatrix Medical Group from $14.50 to $17.00 and gave the company a “market perform” rating in a research report on Friday, September 5th. Wall Street Zen raised Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 4th. UBS Group raised their price objective on Pediatrix Medical Group from $16.50 to $23.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.